Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 1 · 25%

Anti‐VEGF vs steroids

BCVA: gain of 15 or more ETDRS letters · people with BRVO

Anti‐VEGF leads to higher gain of 15 letters or more of visual acuity compared with steroid (high certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
RR 1.67 [1.33, 2.1]
2 studies · 330 participants
High

Anti‐VEGF vs laser

BCVA: gain of 15 or more ETDRS letters · people with BRVO

Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity compared with laser (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
RR 2.09 [1.44, 3.05]
2 studies · 201 participants
Moderate

Anti‐VEGF vs sham

Gain of 15 letters or more of visual acuity at 6 months · macular oedema secondary to branch retinal vein occlusion

Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity at 6 months compared with sham (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
RR 1.72 [1.19, 2.49]
1 study · 283 participants
Moderate

Anti‐VEGF vs control

BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher gain of 15 or more letters visual acuity at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 4.19 [2.32, 7.55]
6 studies · 2667 participants
Moderate